Form D · Investing

PharmaCan Capital Corp.

Toronto, A6 · CIK 0001656472

Offering snapshot reported May 27, 2016 · SEC filing

Reported sold
$4.64M
Offering amount: $10.8M
Investors reported
21
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 13, 2016
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 27, 2016Initial$4,636,800No comparison21SEC filing
Oct 23, 2015Initial$1,147,800No comparison6SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired, Other
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-264049
The total amount remaining to be sold represents the purchase price of shares purchasable upon exercise of warrants sold in the offering. US dollar amounts were calculated based on the 0.7728 Bank of Canada noon exchange rate in effect on 5-13-16.
Units, each comprised of one common share and one common share purchase warrant exercisable at Cdn$0.245 per warrant share for 5 years

Source: Form D, filed May 27, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Alan Friedman Director
Lorne Gertner Director
Michael Gorenstein Director, Executive
Glen Huber Executive
Steven Isenberg Director
Michael Howard Krestell Director
Ryan Roebuck Director
Paul Rosen Director, Executive

Issuer details

Industry: Investing (See others in industry)

Address:
76 Stafford Street, Suite 302
Toronto, A6, M6J 2S1